APA (7th ed.) Citation

AM, G., X, L., RH, A., MC, G., JL, M., V, V., . . . F, M. (2015). Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical breast cancer, 15(5), 325. https://doi.org/10.1016/j.clbc.2015.03.004

Chicago Style (17th ed.) Citation

AM, Gonzalez-Angulo, et al. "Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer." Clinical Breast Cancer 15, no. 5 (2015): 325. https://doi.org/10.1016/j.clbc.2015.03.004.

MLA (9th ed.) Citation

AM, Gonzalez-Angulo, et al. "Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer." Clinical Breast Cancer, vol. 15, no. 5, 2015, p. 325, https://doi.org/10.1016/j.clbc.2015.03.004.